About Biolexis Therapeutics
Biolexis Therapeutics is a Healthcare company based in Salt Lake City (United States) founded in 2021 by David J Bearss and Hariprasad Vankayalapati. CRO focused on drug discovery of small molecule therapeutics. Biolexis Therapeutics has raised $14.1 million across 5 funding rounds from investors including Clarke Capital Partners. Biolexis Therapeutics offers products and services including Anti-obesity drugs, AMPK activators, mTORC inhibitors, and TNIK inhibitors. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Cell and Molecular Biology. Its competitors include Medeloop, Hyku Biosciences and Centivax; 3 of its 3 listed competitors have raised funding.
Company details
Biolexis Therapeutics was founded in 2021 and is based in Salt Lake City, United States. Operations are centered on contract research organization services within the biotechnology sector. Drug discovery efforts for small molecule therapeutics are emphasized, with support provided for early-stage development processes. Co-founders David J. Bearss and Hariprasad Vankayalapati lead the initiative focused on advancing therapeutic innovations.
- Headquarters Salt Lake City, United States
- Founders David J Bearss, Hariprasad Vankayalapati
- SectorsHealthcare
- Website biolexistx.com
- Social LinkedIn
- Legal Name Biolexis Therapeutics
- Total Equity Funding$14.1M (USD)
in 5 rounds
- Latest Funding Round$1.6M (USD), Series A
May 2026
- Investors
Products & Services of Biolexis Therapeutics
Biolexis Therapeutics offers a comprehensive portfolio of products and services, including Anti-obesity drugs, AMPK activators, mTORC inhibitors, and TNIK inhibitors.
Targets GLP-1 for obesity treatment and reduces side effects.
Activates protein kinase for obesity and overall health benefits.
Inhibits pathways to address longevity and chronic diseases.
Develops inhibitors for metabolic and related health issues.
Funding Insights of Biolexis Therapeutics
Biolexis Therapeutics has successfully raised a total of $14.1M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $1.6 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.1M
- Total Rounds 5
- Last Round Series A — $1.6M
- First Round $1.5M
(Feb 2022)
- Investors Count 1
All 5 funding rounds of Biolexis Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $1.6M | Series A | – | – | – |
| Nov 2023 | $10M | Series A | – | Clarke Capital Partners | – |
| Oct 2023 | $1M | Seed | – | – | – |
| Sep 2022 | $1.5M | Seed | – | – | – |
| Feb 2022 | $1.5M | Debt – Conventional | – | – | – |
1 investors in total: 1 institutional.
Investors in Biolexis Therapeutics
Biolexis Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Clarke Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment expertise is utilized by Clarke Capital Partners to grow businesses. | 2005 | clarkecp.com | Draper, United States |
Investor details for Biolexis Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biolexis Therapeutics
3 people are tracked at Biolexis Therapeutics (3 in leadership).
| Name | Role | Group |
|---|---|---|
David J Bearss | Co-Founder | Leadership |
Hariprasad Vankayalapati | Co-Founder | Leadership |
Micah Harman | Director Of Marketing | Leadership |
Complete people profiles for Biolexis Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Biolexis Therapeutics
3 dated milestones of Biolexis Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Biolexis Therapeutics is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Series A, of $1.6M.
Competitors of Biolexis Therapeutics
Biolexis Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Medeloop, Hyku Biosciences and Centivax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| medeloop.ai | 2021 | Palo Alto, United States | $23.5M | Drug discovery services are offered by Medeloop as a CRO. | ||
| hykubiosciences.com | 2023 | Lexington, United States | $56M | Covalent medicines platform is advanced for drug discovery targeting proteins. | ||
| centivax.com | 2019 | San Francisco, United States | $55M | Drug discovery services are provided to pharmaceutical and biotech clients. |
Detailed competitors of Biolexis Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biolexis Therapeutics
The website of Biolexis Therapeutics (biolexistx.com) receives about 2.1K visits a month.
- Monthly visits2.1K
▲ 698.2% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Biolexis Therapeutics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biolexis Therapeutics
Complete news archive for Biolexis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biolexis Therapeutics
Biolexis Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Biolexis Therapeutics is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Biolexis Therapeutics is a funded company, having raised a total of $14.1M across 5 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $1.5M, raised on Feb 2022.
Biolexis Therapeutics was founded in 2021 and is based in Salt Lake City, United States. Operations are centered on contract research organization services within the biotechnology sector. Drug discovery efforts for small molecule therapeutics are emphasized, with support provided for early-stage development processes. Co-founders David J. Bearss and Hariprasad Vankayalapati lead the initiative focused on advancing therapeutic innovations.
Biolexis Therapeutics's top competitors include Medeloop, Centivax and Hyku Biosciences.
Biolexis Therapeutics offers Anti-obesity drugs, AMPK activators, mTORC inhibitors, and TNIK inhibitors.
Biolexis Therapeutics has 1 investor. Key investors include Clarke Capital Partners.
Biolexis Therapeutics operates through Biolexis Therapeutics.